A cannabinoid-based product reduced papillary thyroid carcinoma cell viability in a dose- and time-dependent manner while upregulating the tumor suppressor gene p53 and downregulating cancer-promoting genes BCL-2 and c-Myc.
cancer researchers, endocrinologists, cannabinoid pharmacologists
What the researchers found
The cannabinoid product BRF1A decreased K1 papillary thyroid cancer cell viability dose- and time-dependently. Within 24 hours, it increased TP53 gene expression (tumor suppressor) while decreasing BCL-2 (anti-apoptotic) and c-Myc (proliferation) gene expression, suggesting a pro-apoptotic mechanism.
Why it matters
Papillary thyroid carcinoma is the most common thyroid cancer. While surgery is effective, non-invasive therapeutic options are being explored. This study provides initial evidence that cannabinoids may affect thyroid cancer cells through well-characterized anti-cancer pathways.
The numbers in context
K1 cell line (PTC cells). BRF1A: dose- and time-dependent cytotoxicity. 24-hour effects: TP53 upregulated, BCL-2 downregulated, c-Myc downregulated. 48-hour time point also assessed.
How the study worked
In vitro study using K1 papillary thyroid cancer cell line derived from metastatic well-differentiated PTC. BRF1A co-cultured with cells at 37°C. Cell viability assessed by trypan blue exclusion. Gene expression measured by qRT-PCR at 24 and 48 hours.
What this study cannot tell us
Single cell line in vitro study. Proprietary cannabinoid product (BRF1A) — specific composition unclear. No comparison to standard treatments. No in vivo validation. Cannot predict clinical efficacy from cell culture results.
How to read the evidence
Early-stage in vitro study on a single cell line with a proprietary product. Interesting mechanistic findings but far from clinical relevance.
When this study was published
2025 publication.
The bigger picture
The p53/BCL-2/c-Myc pathway is a well-established cancer signaling axis. Showing cannabinoid modulation of these specific genes in thyroid cancer adds to the growing preclinical evidence of cannabinoid anti-cancer properties, though translation to clinical use remains distant.
Questions still open
- What specific cannabinoids in BRF1A are responsible for the anti-cancer effects?
- Would these effects translate to animal models of thyroid cancer?
Common questions
Can cannabinoids treat thyroid cancer?
How might cannabinoids fight cancer?
Read the original research
Cannabinoid Derived Product is a Potential Novel Therapeutic for Papillary Thyroid Carcinoma.
Integrative cancer therapies, 24, 15347354251332966
Citation
Taico Oliva, Carolina; Musa, Ibrahim; Ardalani, Fariba; Breslin, Joseph; Yang, Nan; Moscatello, Augustine; Rotsides, Janine; Tiwari, Raj; Geliebter, Jan; Li, Xiu-Min. (2025). Cannabinoid Derived Product is a Potential Novel Therapeutic for Papillary Thyroid Carcinoma.. Integrative cancer therapies, 24, 15347354251332966. https://doi.org/10.1177/15347354251332966
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk